Investigations into state-of-the-art treatment for hepatocellular carcinoma
NYU’s GI investigators are currently conducting protocols using bevacizumab, sorafenib and anti-angiogenic drugs to treat patients with hepatocellular carcinoma.
A new, exciting trial using organic arsenic to treat patients with inoperable advanced hepatoma will further add to the range of treatment options for this difficult disease.